



For Immediate Release:

Date: October 18, 2011

Progenika Inc. Opens New Facility in Medford

Contacts:

Angus G. McQuilken, MLSC VP for Communications
(617) 921-7749 amcquilken@masslifesciences.com

Sarah MacDonald, MassBio VP of Development & Communications
(617) 674-5115 sarah.macdonald@massbio.org

Ander Caballero, COO, Progenika
(617) 500-5101 acaballero@progenika.com

MEDFORD, MA – Spain-based genotyping microarray producer Progenika officially opened the company's new US headquarters in Medford, Massachusetts today. The event included a tour of the facility, with participation from President of the Basque region of Spain Patxi Lopez, Progenika co-CEO Antonio Martinez, Progenika COO Ander Caballero, Massachusetts Life Sciences Center President & CEO Susan Windham-Bannister, Massachusetts Office of International Trade and Investment Associate Director Elizabeth Steele, and MassBio Director of Economic Development & Global Affairs Peter Abair. The company's new office and lab facility is located at 200 River's Edge Drive in Medford. The company's US headquarters was formerly located in Cambridge.

"Progenika has always seen Massachusetts as the center of excellence in technology and a focus of innovation and science. That was the reason why we decided to establish in the Commonwealth in 2007" said Antonio Martinez. "Investing in brand new facilities with a specifically designed and extended CLIA laboratory space reaffirms Progenika's commitment with Massachusetts in the field of biotechnology."

"Massachusetts is a center for innovation in science and technology, and Progenika's investment in a new facility here attests to the strength of our life sciences cluster and the economic opportunity it brings," said Windham-Bannister. "We look forward to an ongoing partnership with Progenika as they continue to grow here in the Commonwealth."

"Progenika is a great example of an international company not only locating here in Massachusetts, but growing its business in following years. We applaud Progenika on their expansion and wish them well in their new facilities," said Ken Brown, Executive Director of the Massachusetts Office of International Trade & Investment.

About Progenika:

Progenika Biopharma is a leading biotech company in the field of Personalized Medicine that designs, produces and commercializes in vitro diagnostics tests and DNA genotyping microarrays. Progenika's portfolio covers a broad range of clinical needs from the diagnosis and prognosis of complex diseases, to the prediction of response and monitoring of effectiveness for different treatments. These activities are performed by a multidisciplinary team of more than 60 scientists (biochemists, biologists, computer biologists, etc.), technicians and administrative staff.

Progenika has developed a number of microarray tests for Blood Group genotyping (BLOODchip) which will be internationally distributed by Grifols and by Novartis in the USA, identification of Familial Hypercholesterolemia (ADH) as well as a wide variety of services including monitoring treatments with biological drugs on inflammatory diseases a number of gene sequencing tests.

Progenika, Inc. is based in Medford, Massachusetts, where service is provided through its brand new CLIA certified laboratory and dedicated office space and personnel.

-end-